Cresco Labs and Columbia Care Terminate $2 Billion Merger

Key Takeaway

The largest proposed cannabis merger in US history collapsed when Cresco Labs and Columbia Care mutually terminated their $2 billion all-stock deal. The companies had been unable to divest enough assets to satisfy state regulatory divestiture requirements by the agreement's deadline, particularly in New York, Illinois, and Ohio where the combined entity would have exceeded license caps. The termination was mutual and neither party paid a break-up fee. The failure reflected broader challenges facing cannabis M&A, including regulatory fragmentation across states, cash-strapped buyers, and declining valuations that made deal economics work less often. For cannabis operators, the Cresco-Columbia collapse signaled that large transformational cannabis mergers would remain difficult.